UCB (EBR:UCB) UCB Media Room: Acquisition of own shares
Directive transparence : information réglementée Communiqué sur comptes, résultats, chiffres d’affaires
17/03/2023 20:00
https://mb.cision.com/Public/18595/3736472/8b0007373e7b6fa5_800x800ar.png
** Acquisition of own shares
------------------------------------------------------------
Brussels (Belgium), 17 March 2023 =E2=80=93 20:00 (CET) =E2=80=93 Regulated=
information=C2=A0
Acquisition of own shares
In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi=
ng the Belgian Code on Companies and Associations, UCB SA/NV (=E2=80=9CUCB=
=E2=80=9D or the =E2=80=9CCompany) (Euronext Brussels: UCB) hereby disclose=
s certain information in relation to its Share Repurchase Program 2023.=C2=
=A0
Under this program, UCB has requested a financial intermediary to repurchas=
e up to 500 000 UCB shares on its behalf under the terms of a discretionary=
mandate agreement with initial validity until 28 April 2023, effective as =
from 27 February 2023, to cover current and future obligations under UCB's =
Long Term Incentive Plans for its personnel.
In the framework of this Share Repurchase Program 2023, UCB repurchased 177=
499 UCB shares on Euronext Brussels in the period from 10 March 2023 up to=
and including 16 March 2023, as follows:=C2=A0
https://mb.cision.com/Public/18595/3736472/b87dab45450bdd21_800x800ar.png
This press release is available on UCB SA/NV=E2=80=99s website via the foll=
owing link (https://www.ucb.com/stories-media/Press-Releases) .
For further information, contact UCB:=C2=A0
Investor Relations
Antje Witte=C2=A0
T +32 2 559 94 14
antje.witte@ucb.com
Corporate Communications
Laurent Schots=C2=A0
T+32 2 559 92 64
laurent.schots@ucb.com =C2=A0=C2=A0 =C2=A0
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8 700 peopl=
e in 36 countries, the company generated revenue of =E2=82=AC 5.5 billion i=
n 2022. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twit=
ter: @UCB_news
=C2=A0
GenericFile
230317 - Rachat d actions propres FR final (https://mb.cision.com/Public/18=
595/3736472/bc2a9e94de122575.pdf) GenericFile
230317 - Acquisition of own shares ENG final (https://mb.cision.com/Public/=
18595/3736472/9de839fab6a2c37a.pdf) GenericFile
230317 - Verwerving van eigen aandelen NL final (https://mb.cision.com/Publ=
ic/18595/3736472/83f2fb7f1067c63f.pdf) Image
Chart 1 March 17 2023 (https://mb.cision.com/Public/18595/3736472/b87dab454=
50bdd21_org.png)
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x131588x1x6868579x2400=
0x6&Email=3Dregnews%40symexglobal.com.
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium
26/04/2024 20:00
25/04/2024 18:00
25/04/2024 07:01
23/04/2024 20:00
22/04/2024 07:01
19/04/2024 20:00
17/04/2024 07:01
12/04/2024 20:00
12/04/2024 18:01
12/04/2024 07:01